Please assess the completion status of the following clinical trial:

Trial Title: In-office Placement of the Propel Mini Sinus Implant in the Frontal Sinus Ostia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Patient has provided written informed consent using a form approved by the reviewing IRB.~* Patient is 18 years of age or older.~* Patient is willing and able to comply with protocol requirements.~* Patient has CRS defined as sinonasal inflammation persisting for more than 12 weeks and complains of at least 2 of the 4 following symptoms: nasal blockage/obstruction/congestion, nasal blockage/obstruction/congestion, nasal discharge (anterior/posterior), facial pain/pressure, reduction/loss of smell~* CRS diagnosis confirmed by CT scan within 3 months prior to enrollment~* Bilateral frontal sinusitis confirmed by Lund-Mackay score of ≥1 on each side~* Post-endoscopic sinus surgery, patient has bilateral obstruction of the frontal sinus ostia by scarring and/or polypoid edema.~* Patient is a candidate for an in-office balloon dilation procedure.~* In the opinion of the investigator, treatment with the Propel Mini Sinus Implant as an adjunct to balloon sinus dilation is technically feasible and clinically indicated in the frontal sinus ostia.~Exclusion Criteria:~* Expanded amount of ethmoid sinonasal polyps extending beyond the middle meatus of grade 3 or 4 unless reduced prior to randomization in the study.~* Oral-steroid dependent condition such as chronic obstructive pulmonary disease (COPD) or other conditions.~* Known history of allergy or intolerance to corticosteroids or mometasone furoate.~* Clinical evidence of acute bacterial sinusitis or invasive fungal sinusitis.~* Active viral illness (e.g., flu, shingles).~* Clinical evidence of disease or condition expected to compromise survival or ability to complete follow-up assessments through Day 180 post-procedure.~* Currently participating in another clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- PROPEL Mini Sinus Implant (Type: EXPERIMENTAL): Placement of the Propel Mini Sinus Implant in one frontal sinus ostia (FSO) assigned to the treatment group following in-office balloon dilation
- Balloon Sinus Dilation Alone (Type: ACTIVE_COMPARATOR): In-office balloon dilation of the contralateral frontal sinus ostia (FSO) without implant placement

Based on this trial design, predict the completion outcome and termination type (if applicable).